Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 12, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 650,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 12, 2012.
- Price Range: Highest price paid was 1,372.5 pence per share; lowest price paid was 1,358.5 pence per share.
- Treasury Holdings (Settled): 526,940,427 shares (9.68% of total issued share capital).
- Treasury Holdings (Including Unsettled): 528,915,427 shares (10.75% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,918,536,829 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 650,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.75% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (526,940,427 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.68% Treasury ownership calculation.
- Check the status of the 1,975,000 shares purchased but not yet settled to confirm the 10.75% voting rights figure.
- Review the Financial Services Authority's Disclosure and Transparency Rules to understand notification thresholds for shareholders based on the 4,918,536,829 shares in issue.